GERNGERON CORP
Pharmaceutical Preparations
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$68M
- 61% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $57M net debt
- AI in 10-K
- —
Red flags 1 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCFired112× of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $1M | $596K | $237K | — | — | |
| Operating income | −$114M | −$139M | −$194M | −$174M | −$69M | 61% |
| Net income | −$116M | −$142M | −$184M | −$175M | −$84M | 52% |
| Operating cash flow | −$96M | −$127M | −$168M | −$219M | −$111M | 49% |
| Capex | $207K | $431K | $830K | $680K | — | |
| Stock-based comp | $8M | $8M | $19M | $31M | $27M | 15% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 83 | 125 |
| FY2024 | — | — | 223 | 93 |
| FY2023 | — | — | 133 | 94 |
| FY2022 | — | — | 152 | 90 |
| FY2021 | — | — | 77 | 100 |